BOC Sciences has established technology development services that include proven PEGylation processes, purification processes, determination of quality standards & key process parameters, and subsequent formulation development of products. We offer PEG antibody conjugation services and antibody purification processes to our customers.
Fig.1 PEGylated antibody. (Lin et al., 2016)
PEG conjugated antibodies are complexes formed by covalently conjugating a polyethylene glycol (PEG) molecule to an antibody. This conjugation process can alter the properties and functions of the antibody and is often used to improve the performance of antibodies in drug discovery and therapeutics. PEG antibodies are usually prepared chemically, most commonly by chemically reacting the PEG with the active site (e.g., the amino or thiol group) of the antibody to form a covalent linkage. The size of the PEG molecule and the binding mode can be adjusted to obtain the desired properties of the PEG antibody.
PEG modification enhances the stability of antibodies, making them more resistant to temperature, pH and proteases. The polyethylene glycol shell provides a protective layer that reduces degradation, aggregation and inactivation of the antibody. This is important for the stability of the antibody during storage, transportation.
PEG modification reduces the immunogenicity of an antibody, decreasing its recognition and clearance by the immune system. The PEG masks the surface features of the antibody and reduces interaction with the immune system.
PEG antibodies can improve bioavailability in vivo by increasing the molecular size of the antibody and altering its physicochemical properties. This can affect the distribution of the antibody in tissues, targeting and the binding affinity of the antibody to the target.
BOC Sciences provides PEGylation services to obtain PEGylated antibodies to the target through various modifications, such as N-terminal modification, sulfhydryl modification, and carboxyl modification.
First, appropriate functional groups are introduced at the N-terminus of the PEG compounds, which are designed to react with the N-terminal amino group of the antibodies. Then, in order to expose the N-terminal amino group of the antibody, it is usually necessary to remove the Fc region of the antibody. Subsequently, the activated PEG compound is reacted with the antibody with the Fc region removed to achieve PEG modification of the N-terminal amino group. Currently, we adopt the targeted modification of the N-terminal amino group, which can effectively maintain the original biological activity of the drug.
Combined with our advanced technology, we can introduce sulfhydryl group or some specific groups into the pre-determined site of the antibody, and then carry out the modification of the group, so as to obtain the fixed-point modification product with higher retention of activity and reduced immunogenicity.
By modifying the carboxyl group of the antibody with a polyethylene glycol derivative with a hydrazide activating group, a targeted modification product can be obtained.
After completing the PEGylated antibody, purification of the antibody is required, and a suitable purification solution can be selected based on the nature of the product and the application.
Our Advantages
Project Workflow
Reference